Evidence map›Paper›PMID 37737166›Full record

ArticleBMC medical imaging2023

Added value of CE-CT radiomics to predict high Ki-67 expression in hepatocellular carcinoma.

Yu-Meng Zhao, Shuang-Shuang Xie, Jian Wang, Ya-Min Zhang, Wen-Cui Li, Zhao-Xiang Ye, Wen Shen

Open access · goldAbstract read
In one paragraph

Article in BMC medical imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Evaluation and prediction of Ki-67 expression in hepatocellular carcinoma.World journal of gastrointestinal oncology · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yu-Meng ZhaoMedical School of Nankai University, No. 94, Weijin Road, Nankai District, Tianjin, China.
Shuang-Shuang XieDepartment of Radiology, Tianjin First Center Hospital, Tianjin Institute of imaging medicine, School of Medicine, Nankai University, Nankai District, No. 24 Fukang Road, Tianjin, China.
Jian WangDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, School of Medicine, Nankai University, Nankai District, No. 24 Fukang Road, Tianjin, China.
Ya-Min ZhangDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, School of Medicine, Nankai University, Nankai District, No. 24 Fukang Road, Tianjin, China.
Wen-Cui LiDepartment of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.
Zhao-Xiang YeDepartment of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.
Wen ShenDepartment of Radiology, Tianjin First Center Hospital, Tianjin Institute of imaging medicine, School of Medicine, Nankai University, Nankai District, No. 24 Fukang Road, Tianjin, China. shenwen66happy@126.com.
Nankai University · CNTianjin Medical University · CNTianjin Medical University Cancer Institute and Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to develop a computed tomography (CT) model to predict Ki-67 expression in hepatocellular carcinoma (HCC) and to examine the added value of radiomics to clinico-radiological features.

methodsA total of 208 patients (training set, n = 120; internal test set, n = 51; external validation set, n = 37) with pathologically confirmed HCC who underwent contrast-enhanced CT (CE-CT) within 1 month before surgery were retrospectively included from January 2014 to September 2021. Radiomics features were extracted and selected from three phases of CE-CT images, least absolute shrinkage and selection operator regression (LASSO) was used to select features, and the rad-score was calculated. CE-CT imaging and clinical features were selected using univariate and multivariate analyses, respectively. Three prediction models, including clinic-radiologic (CR) model, rad-score (R) model, and clinic-radiologic-radiomic (CRR) model, were developed and validated using logistic regression analysis. The performance of different models for predicting Ki-67 expression was evaluated using the area under the receiver operating characteristic curve (AUROC) and decision curve analysis (DCA).

resultsHCCs with high Ki-67 expression were more likely to have high serum α-fetoprotein levels (P = 0.041, odds ratio [OR] 2.54, 95% confidence interval [CI]: 1.04-6.21), non-rim arterial phase hyperenhancement (P = 0.001, OR 15.13, 95% CI 2.87-79.76), portal vein tumor thrombus (P = 0.035, OR 3.19, 95% CI: 1.08-9.37), and two-trait predictor of venous invasion (P = 0.026, OR 14.04, 95% CI: 1.39-144.32). The CR model achieved relatively good and stable performance compared with the R model (AUC, 0.805 [95% CI: 0.683-0.926] vs. 0.678 [95% CI: 0.536-0.839], P = 0.211; and 0.805 [95% CI: 0.657-0.953] vs. 0.667 [95% CI: 0.495-0.839], P = 0.135) in the internal and external validation sets. After combining the CR model with the R model, the AUC of the CRR model increased to 0.903 (95% CI: 0.849-0.956) in the training set, which was significantly higher than that of the CR model (P = 0.0148). However, no significant differences were found between the CRR and CR models in the internal and external validation sets (P = 0.264 and P = 0.084, respectively).

conclusionsPreoperative models based on clinical and CE-CT imaging features can be used to predict HCC with high Ki-67 expression accurately. However, radiomics cannot provide added value.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHumansKi-67 AntigenRetrospective StudiesTomography, X-Ray ComputedKi-67 AntigenContrast-enhanced computed tomographyHepatocellular carcinomaKi-67 expressionRadiomics

Identifiers

PMID37737166
PMCPMC10514983
OpenAlexW4386945054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.